CMS needs to improve oversight of Medicare Part B drug payment calculations, OIG report finds
(By Jakob Emerson for Becker’s Hospital Review)
CMS needs better strategies to ensure proper oversight of Medicare Part B drug payment calculations, according to a Dec. 3 report from HHS’ Office of the Inspector General.
Medicare members spend about $40 billion every year on Part B prescription drugs and biologicals. CMS uses the manufacturer-reported average sales price for the drug from quarterly sales to calculate provider payments for the drug. Continue reading here…
Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org